Robust performance of generics in H1 19
14/08/19 -"Hikma reported a strong performance in H1 19, with revenue growth of 8% (at CER), primarily attributable to a better-than-expected performance of Generics (+11%), along with an in line performance of ..."
Pages
50
Language
English
Published on
14/08/19
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated